 SAN DIEGO, March 08, 2021 GLOBE NEWSWIRE -- Fate Therapeutics, Inc. the Company or Fate Therapeutics NASDAQ: FATE, a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will present at the following upcoming investor conferences: 